EGFR and K-RAS Gene Status in Lung Cancer
Author Information
Author(s): Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A
Primary Institution: University of Crete
Hypothesis
The study investigates the mutation status of EGFR and K-RAS genes in primary tumors and corresponding metastases in patients with non-small-cell lung cancer (NSCLC).
Conclusion
There is substantial discordance in EGFR and K-RAS mutational status between primary tumors and corresponding metastases in patients with NSCLC, which may have therapeutic implications.
Supporting Evidence
- EGFR mutations were found in 20% of primary tumors but only in 12% of metastases.
- K-RAS mutations were detected in 20% of both primary tumors and metastases.
- Discordance in EGFR mutation status was observed in 28% of patients.
- Discordance in K-RAS mutation status was observed in 24% of patients.
Takeaway
This study found that the genes related to lung cancer can change between the original tumor and its spread, which could affect treatment choices.
Methodology
The study analyzed the mutation status of EGFR and K-RAS genes in primary tumors and corresponding metastases from 25 patients with NSCLC.
Limitations
The study is retrospective and may not account for all variables affecting mutation status.
Participant Demographics
The median age of participants was 55 years, with 88% being men and 88% being active or former smokers.
Statistical Information
P-Value
0.688
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website